Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

130.28 +1.10 (+0.86%)
Streaming Delayed Price Updated: 1:27 PM EDT, Jun 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2 3 4 5 6 7 8 9
...
74 75 Next >
News headline image
Gilead Applauds Collaborative Efforts to Launch Lenacapavir for HIV Prevention in South Africa
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Sciences and Lakefront Complete Acquisition of Ouro Medicines to Further Expand Inflammation Pipeline
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Biotech ETFs: Which ETF Offers Lower Fees? IBBQ or XPH? ↗
Compare diversification strategies and see how each ETF's unique index focus shapes risk and return for healthcare sector investors. 
Via The Motley Fool
Topics ETFs
News headline image
Gilead Advances Liver Disease Ambitions With Encouraging Study Outcome ↗
Gilead reports positive Phase 3 Livdelzi data in PBC, with more patients achieving ALP normalization versus placebo after 52 weeks. 
Via Benzinga
Gilead Sciences (NASDAQ:GILD) Screens as a Top Dividend Stock with Strong Profitability and Health ↗
Via Chartmill
Gilead Sciences Inc (NASDAQ:GILD) Beats Q1 Estimates But Stock Falls on Hefty Acquisition Costs and Revised Loss Guidance ↗
Via Chartmill
News headline image
Gilead’s Livdelzi® (Seladelpar) Delivers Statistically Significant Composite ALP Normalization in Phase 3 IDEAL Trial in Primary Biliary Cholangitis (PBC)
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Here's How Much $1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth Today ↗
 
Via Benzinga
News headline image
Tango Therapeutics Stock Is Up 840%, and This Fund Just Disclosed Buying $164 Million More ↗
This biotechnology firm advances targeted cancer therapies, leveraging genetic insights and strategic partnerships in oncology. 
Via The Motley Fool
News headline image
Phase 3 ASSURE Interim Data: Majority of People in the Study with ALP 1–1.67×ULN Achieved High and Sustained Composite ALP Normalization at 24 Months with Gilead’s Livdelzi (Seladelpar)
From Gilead Sciences, Inc.
Via Business Wire
News headline image
If You Invested $1000 In Gilead Sciences Stock 15 Years Ago, You Would Have This Much Today ↗
 
Via Benzinga
News headline image
Gilead Sciences Highlights Trodelvy Lung Data, Long-Acting HIV Pipeline at RBC Conference ↗
Gilead Sciences (NASDAQ:GILD) Chief Medical Officer Dietmar Berger outlined several upcoming clinical and regulatory priorities across oncology, inflammation and HIV during a discussion with RBC... 
Via MarketBeat
News headline image
FDA Grants Accelerated Approval to Gilead’s Hepcludex® (bulevirtide-gmod), the First and Only Approved Treatment for Chronic Hepatitis Delta Virus (HDV)
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Receives CHMP Positive Opinion for Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer for Patients Not Candidates for PD-(L)1 Inhibitors
From Gilead Sciences, Inc.
Via Business Wire
News headline image
New ASCO and EHA 2026 Data Demonstrate Gilead and Kite’s Momentum Across Antibody-Drug Conjugates and Cell Therapy in Oncology
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Sciences Completes Acquisition of Tubulis Further Strengthening Oncology Portfolio
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Sciences and World Health Organization Expand Collaboration to Help Eliminate Visceral Leishmaniasis, a Fatal Parasitic Disease
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Compugen Q1 Earnings Call Highlights ↗
Compugen (NASDAQ:CGEN) said it remains on track to report interim progression-free survival data in the first quarter of 2027 from its MAIA-ovarian study, as the clinical-stage immuno-oncology company... 
Via MarketBeat
Topics Earnings
News headline image
Gilead Sciences Leans on HIV Growth as Deals Build Oncology, Inflammation Pipeline ↗
Gilead Sciences (NASDAQ:GILD) Chief Commercial Officer and Head of Corporate Affairs Johanna Mercier said the company is leaning on its HIV business while continuing to build out oncology and... 
Via MarketBeat
News headline image
3 Market-Beating Stocks to Research Further
The best-performing stocks typically have robust sales growth, increasing margins, and rising returns on capital, and those that can maintain this trifecta y... 
Via StockStory
News headline image
Gilead Prices $3 Billion of Senior Unsecured Notes
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Assembly Biosciences Touts HSV, Hepatitis D Catalysts at BofA Conference ↗
Assembly Biosciences (NASDAQ:ASMB) Chief Medical Officer Anuj Gaggar outlined the company’s virology strategy and upcoming clinical priorities during a Bank of America-hosted discussion, emphasizing... 
Via MarketBeat
News headline image
Gilead Sciences’s Q1 Earnings Call: Our Top 5 Analyst Questions
Gilead Sciences began 2026 with revenue and adjusted earnings per share both exceeding Wall Street expectations, reflecting strong commercial execution and d... 
Via StockStory
Topics Earnings
News headline image
Gilead to Present New Data Advancing Care in PBC and Viral Hepatitis at EASL 2026
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead (GILD) Q1 2026 Earnings Call Transcript ↗
Gilead (GILD) Q1 2026 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
These S&P500 stocks are moving in today's pre-market session ↗
Via Chartmill
News headline image
GILD Q1 Deep Dive: HIV Growth, Oncology Pipeline, and Margin Management Shape 2026 Outlook
Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) reported revenue ahead of Wall Street’s expectations in Q1 CY2026, with sales up 4.4% year on year to... 
Via StockStory
What's going on in today's after hours session: S&P500 movers ↗
Via Chartmill
News headline image
Gilead Sciences’s (NASDAQ:GILD) Q1 CY2026: Beats On Revenue
Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) reported Q1 CY2026 results topping the market’s revenue expectations, with sales up 4.4% year on year... 
Via StockStory
News headline image
Gilead Tumbles On Mixed Guidance Update Amid Recent M&A Frenzy ↗
Gilead Sciences issued a mixed guidance update late Thursday after the biotech company beat first-quarter sales expectations. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9
...
74 75 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.